Skip to Content

'
Karen H. Lu, MD

Present Title & Affiliation

Primary Appointment

J. Taylor Wharton Distinguished Chair in Gynecologic Oncology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Chair, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Graduate Faculty, Regular Member, Graduate School of Biomedical Sciences. The University of Texas Health Science Center, Houston, TX

Bio Statement

Dr. Lu is Professor in the Department of Gynecologic Oncology and Reproductive Medicine and holds the H.E.B. Professorship in Cancer Research. Her main clinical interests include the surgical and medical treatment of women with ovarian and endometrial cancers, as well as the management of women at genetically high risk for these cancers. She serves as Co-Director for the MD Anderson Clinical Cancer Genetics Program and Director of the High Risk Ovarian Cancer Screening Clinic. She is a national leader in the cancer genetics field and has published seminal articles on hereditary gynecologic cancers. In addition, she serves as Director of the Uterine Cancer Research Program (UCRP) and Principal Investigator of the NCI-sponsored Uterine Cancer Specialized Program of Research Excellence (SPORE). She leads a research team that aims to apply laboratory-based findings to improving the care of gynecologic cancer patients. She receives support for her research from the National Cancer Institute, the Lynne Cohen Foundation, the American Gynecologic and Obstetric Society, and the Ovarian Cancer Research Fund. She has published numerous articles and book chapters and has served as a visiting professor at many academic institutions.  She serves on the American Society of Clinical Oncology (ASCO) Cancer Prevention Committee, the NCI PDQ Editorial Board for Cancer Genetics and the American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice Bulletins. In addition, she takes pride in having mentored many clinical fellows and trainees and has been awarded an M.D. Anderson Outstanding Educator Award. She has consistently been featured as one of America’s Top Doctors.

 

Education & Training

Degree-Granting Education

1991 Yale University School of Medicine, New Haven, CT, MD
1986 Harvard University, Cambridge, MA, BA, Biochemical Sciences, cum laude

Postgraduate Training

9/2011-4/2012 Executive Leadership in Academic Medicine (ELAM), Drexel University College of Medicine, Philadelphia, PA
11/2007-4/2008 Clinical Safety and Effectiveness Training Program, The University of Texas MD Anderson Cancer Center, Houston, TX
1996-1999 Fellowship, Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA
1991-1995 Internship and Residency, Obstetrics and Gynecology, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA

Board Certifications

2003 American Board of Obstetrics and Gynecology, Diplomate, Div of Gynecologic Oncology
2001 American Board of Obstetrics and Gynecology, Diplomate
1992 National Board of Medical Examiners, Diplomate

Experience/Service

Academic Appointments

Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-10/2012
Associate Professor, Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/2004-8/2008
Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, 1999-2004
Instructor, Harvard Medical School, Boston, MA, 1995-1996

Administrative Appointments/Responsibilities

Co-Director, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-present

Institutional Committee Activities

Member, 2011 Faculty Achievement Awards Committee, 5/2011

Honors and Awards

2011 Finalist, Julie and Ben Rogers Award for Excellence, The University of Texas MD Anderson Cancer Center
2010 2010 Faculty Achievement Award in Cancer Prevention, MD Anderson Cancer Center, The Margaret and James A. Elkins, Jr. Faculty Achievement Award in Cancer Prevention
2009-2010 Best Doctors in America, Best Doctors
2009 America's Top Doctors for Cancer, Castle Connally Medical LTD
2007 Faculty Educator of the Month (October), UT MD Anderson Cancer Center
2007 Medical Honoree Award, Lynne Cohen Foundation
2004 Mischell Award, Wyeth Annual Therapeutic Options for Menopausal Health Confrerence
2003 Outstanding Educator Award, M.D. Anderson
2001-2004 Liz Tilberis Scholar Award, Ovarian Cancer Research Fund
1999-2002 Burroughs Wellcome Award, American Association of Obstetricians and Gynecologists Foundation (AAOGF)
1998-1999 Academic Training Award, American College of Obstetrics and Gynecology, ORTHO
1995 APGO/CREOG Parke-Davis Scholars Award
1994-1995 Administrative Chief Resident, Harvard Medical School
1990 Farr Scholar, Yale Medical School
1990 Summer Research Fellowship, Yale Medical School
1986 Radcliffe Travelling Fellowship, Harvard and Radcliffe Colleges
1986 Thomas Hoopes Prize "for outstanding undergraduate thesis", Harvard University

Selected Publications

Peer-Reviewed Original Research Articles

1. Cuellar-Partida G, Lu Y, Dixon SC, Australian Ovarian Cancer Study, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Høgdall C, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeney LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Blake Gilks C, Gronwald J, Jakubowska A, Lubinski J, Kluz T, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PD, Webb PM, Chenevix-Trench G, Risch HA, MacGregor S. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135(7):741-56, 7/2016. e-Pub 4/13/2016. PMID: 27075448.
2. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A, Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H, Breast Cancer Family Register, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KB, Collée JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Silva Idos S, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejlertsen B, Ekici AB, Ellis SD, EMBRACE, Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley BL, Friebel T, Friedman E, Friel G, Frost D, Garber J, García-Closas M, Gayther SA, GEMO Study Collaborators, GENICA Network, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goodman MT, Gore M, Greene MH, Grip M, Gronwald J, Gschwantler Kaulich D, Guénel P, Guzman SR, Haeberle L, Haiman CA, Hall P, Halverson SL, Hamann U, Hansen TV, Harter P, Hartikainen JM, Healey S, HEBON, Hein A, Heitz F, Henderson BE, Herzog J, T Hildebrandt MA, Høgdall CK, Høgdall E, Hogervorst FB, Hopper JL, Humphreys K, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A, Jens. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141(2):386-401, 5/2016. e-Pub 5/2/2015. PMCID: PMC4630206.
3. Gockley AA, Rauh-Hain JA, Anders AM, Meyer LA, Clemmer J, Lu KH, Clark RM, Schorge JO, Del Carmen MG. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis. Int J Gynecol Cancer 26(4):697-704, 5/2016. e-Pub 1/29/2016. PMID: 26825834.
4. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol 77(5):973-7, 5/2016. e-Pub 3/24/2016. PMID: 27014780.
5. Di Guilmi J, Salvo G, Mehran R, Sood AK, Coleman RL, Lu KH, Vaporciyan A, Ramirez PT. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer 26(4):801-6, 5/2016. e-Pub 3/3/2016. PMID: 26937753.
6. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv 10(2):261-70, 4/2016. e-Pub 8/6/2015. PMCID: PMC4744585.
7. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, EMBRACE, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, Tesoriero A, kConFab Investigators, James PA, Bruinsma F, Campbell IG, Australia Ovarian Cancer Study Group, Broeks A, Schmidt MK, Hogervorst FB, HEBON, Beckman MW, Fasching PA, Fletcher O, Johnson N, Sawyer EJ, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry KL, Poole EM, Tworoger SS, Dorfling CM, van Rensburg EJ, Godwin AK, Guénel P, Truong T, GEMO Study Collaborators, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova OM, Isaacs C, Maugard C, Bojesen SE, Flyger H, Gerdes AM, Hansen TV, Jensen A, Kjaer SK, Hogdall C, Hogdall E, Pedersen IS, Thomassen M, Benitez J, González-Neira A, Osorio A, Hoya Mde L, Segura PP, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John EM, Neuhausen SL, Ding YC, Castillo D, Weitzel JN, Ganz PA, Nussbaum RL, Chan SB, Karlan BY, Lester J, Wu A, Gayther S, Ramus SJ, Sieh W, Whittermore AS, Monteiro AN, Phelan CM, Terry MB, Piedmonte M, Offit K, Robson M, Levine D, Moysich KB, Cannioto R, Olson SH, Daly MB, Nathanson KL, Domchek SM, Lu KH, Liang D, Hildebrant MA, Ness R, Modugno F, Pearce L, Goodman MT, Thompson PJ, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Brüning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari LM, Aittomäki K, Butzow R, Bogdanova NV, Dörk T, Lindblom A, Margolin S, Rantala J, Kosma VM, Mannermaa A, Lambrechts D, Neven P, Claes KB, Maerken TV, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira MR, Collavoli A, Hallberg E, Olson JE, Goode EL, Hart SN, Shimelis H, Cunningham JM, Giles GG, Milne RL, Healey S, Tucker K, Haiman CA, Henderson BE, Goldberg MS, Tischkowitz M, Simard J, Soucy P, Eccles DM, Le N, Borresen-Dale AL,. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst 108(2), 2/2016. e-Pub 11/19/2015. PMCID: PMC4907358.
8. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, Win AK, Senter L, Lipkin SM, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, de la Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S, Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, Terdiman JP, Lu KH, Thibodeau S, Lindor NM. PMS2 monoallelic mutation carriers: the known unknown. Genet Med 18(1):13-9, 1/2016. e-Pub 4/9/2015. PMCID: PMC4834863.
9. McCampbell AS, Mittelstadt ML, Dere R, Kim S, Zhou L, Djordjevic B, Soliman PT, Zhang Q, Wei C, Hursting SD, Lu KH, Broaddus RR, Walker CL. Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity. Curr Mol Med 16(3):252-65, 2016. PMID: 26917264.
10. Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review. Gynecol Oncol 139(3):568-72, 12/2015. e-Pub 9/25/2015. PMID: 26407480.
11. Rauh-Hain JA, Pepin KJ, Meyer LA, Clemmer JT, Lu KH, Rice LW, Uppal S, Schorge JO, Del Carmen MG. Management for Elderly Women With Advanced-Stage, High-Grade Endometrial Cancer. Obstet Gynecol 126(6):1198-206, 12/2015. e-Pub 11/5/2015. PMID: 26551187.
12. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15(11):668-79, 10/23/2015. PMID: 26493647.
13. Ho JC, Allen PK, Jhingran A, Westin SN, Lu KH, Eifel PJ, Klopp AH. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol 139(1):40-6, 10/2015. e-Pub 7/17/2015. PMID: 26193429.
14. Rauh-Hain JA, Diver E, Meyer LA, Clemmer J, Lu KH, Del Carmen MG, Schorge JO. Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: Analysis of the National Cancer Database. Gynecol Oncol 139(1):77-83, 10/2015. e-Pub 8/29/2015. PMID: 26325526.
15. Rauh-Hain JA, Starbuck KD, Meyer LA, Clemmer J, Schorge JO, Lu KH, Del Carmen MG. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: A National Cancer Database analysis. Gynecol Oncol 139(1):84-9, 10/2015. e-Pub 8/22/2015. PMID: 26307402.
16. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol 9(8):1694-703, 10/2015. e-Pub 5/16/2015. PMCID: PMC4584169.
17. Jiang Y, Malouf GG, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Spano JP, Broaddus R, Tannir NM, Khayat D, Lu KH, Su X. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget. e-Pub 9/26/2015. PMID: 26431491.
18. Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, Malpica A, Sun CC. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin Oncol 33(24):2675-82, 8/20/2015. e-Pub 7/20/2015. PMCID: PMC4534528.
19. Lu Y, Cuellar-Partida G, Painter JN, Nyholt DR, Australian Ovarian Cancer Study, International Endogene Consortium (IEC), Morris AP, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Wicklund KG, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeney LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Gilks CB, Gronwald J, Jakubowska A, Lubinski J, Gawelko J, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, Mclaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Risch HA, Goode EL, Schildkraut JM, Webb PM, Pearce CL, Berchuck A, Pharoah PD, Montgomery GW, Zondervan KT, Chenevix-Trench G, McGregor S. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Hum Mol Genet. e-Pub 7/30/2015. PMID: 26231222.
20. Olson SH, De Vivo I, Setiawan VW, Lu KH. Symposium on advances in endometrial cancer epidemiology and biology. Gynecol Oncol. e-Pub 7/29/2015. PMID: 26232339.
21. Dempsey KM, Broaddus R, You YN, Noblin SJ, Mork M, Fellman B, Urbauer D, Daniels M, Lu K. Is it all Lynch syndrome?: An assessment of family history in individuals with mismatch repair-deficient tumors. Genet Med 17(6):476-84, 6/2015. e-Pub 10/23/2014. PMID: 25341111.
22. Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, Ramirez PT. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol 137(3):553-558, 6/2015. e-Pub 3/28/2015. PMID: 25827290.
23. Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J 21(3):260-7, May-Jun, 5/2015. e-Pub 3/19/2015. PMID: 25789811.
24. Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH. Salpingectomy as a Means to Reduce Ovarian Cancer Risk. Cancer Prev Res (Phila) 8(5):342-348, 5/2015. e-Pub 1/13/2015. PMCID: PMC4417454.
25. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, CIMBA Consortium, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen Tv, Ramón y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, De Paepe A, Poppe B, Claes K, De Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomäki K, van der Hout AH, Hog. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347-61, 4/7/2015. PMCID: PMC4537700.
26. Lu KH, Ring KL. One size may not fit all: the debate of universal tumor testing for Lynch syndrome. Gynecol Oncol 137(1):2-3, 4/2015. PMID: 25818039.
27. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 33(8):930-6, 3/10/2015. e-Pub 1/26/2015. PMCID: PMC4348638.
28. Meyer LA, Nick AM, Shi Q, Wang XS, Williams L, Brock T, Iniesta MD, Rangel K, Lu KH, Ramirez PT. Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients. Gynecol Oncol 136(3):440-5, 3/2015. e-Pub 1/31/2015. PMID: 25647455.
29. Daniels MS, Lu KH. Clearer Picture of PMS2-Associated Lynch Syndrome Is Emerging. J Clin Oncol 33(4):299-300, 2/1/2015. e-Pub 12/22/2014. PMID: 25534383.
30. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S, EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM, GEMO Study Collaborators, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus MA, Oosterwijk JC, Breast Cancer Family Registry, Tihomirova L, Tung N, Hamann U, Isaccs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB, HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR, KConFab Investigators, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmalm M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J, Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study Group, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 47(2):164-71, 2/2015. e-Pub 1/12/2015. PMCID: PMC4445140.
31. Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, Lu KH, Roach N, Limburg PJ, American Society of Clinical Oncology, European Society of Clinical Oncology. Hereditary colorectal cancer syndromes: american society of clinical oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European society for medical oncology clinical practice guidelines. J Clin Oncol 33(2):209-17, 1/10/2015. e-Pub 12/1/2014. PMID: 25452455.
32. Shadfan BH, Simmons AR, Simmons GW, Ho A, Wong J, Lu KH, Bast RC, McDevitt JT. A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care. Cancer Prev Res (Phila) 8(1):37-48, 1/2015. e-Pub 11/11/2014. PMCID: PMC4465398.
33. Co NN, Iglesias D, Celestino J, Kwan SY, Mok SC, Schmandt R, Lu KH. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. Cancer 120(22):3457-68, 11/15/2014. e-Pub 7/16/2014. PMCID: PMC4221493.
34. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 32(29):3275-83, 10/10/2014. e-Pub 9/8/2014. PMCID: PMC4178524.
35. Nebgen DR, Lu KH, Rimes S, Keeler E, Broaddus R, Munsell MF, Lynch PM. Combined colonoscopy and endometrial biopsy cancer screening results in women with Lynch syndrome. Gynecol Oncol 135(1):85-9, 10/2014. e-Pub 8/19/2014. PMID: 25149916.
36. Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst 106(9), 9/2014. e-Pub 9/10/2014. PMCID: PMC4200060.
37. Batte BA, Bruegl AS, Daniels MS, Ring KL, Dempsey KM, Djordjevic B, Luthra R, Fellman BM, Lu KH, Broaddus RR. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for lynch syndrome. Gynecol Oncol 134(2):319-25, 8/2014. e-Pub 6/14/2014. PMCID: PMC4125501.
38. Burton-Chase AM, Hovick SR, Sun CC, Boyd-Rogers S, Lynch PM, Lu KH, Peterson SK. Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome. Clin Genet 86(2):185-9, 8/2014. e-Pub 8/27/2013. PMCID: PMC3909028.
39. Bruegl AS, Djordjevic B, Batte B, Daniels M, Fellman B, Urbauer D, Luthra R, Sun C, Lu KH, Broaddus RR. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. Cancer Prev Res (Phila) 7(7):686-97, 7/2014. e-Pub 4/25/2014. PMCID: PMC4090057.
40. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JK. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13(2):291-9, 6/2014. e-Pub 9/26/2013. PMCID: PMC4159051.
41. Nebgen DR, Hartman CL, Rhodes H, Munsell M, Woodard TL, Lu KH. Abnormal uterine bleeding as the presenting symptom of hematopoietic cancer. Obstet Gynecol 123 Suppl 1:30S, 5/2014. PMID: 24770162.
42. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of Prophylactic Salpingectomy with Delayed Oophorectomy as Risk-Reducing Surgery Among BRCA Mutation Carriers. Gynecol Oncol 133(2):283-6, 5/2014. e-Pub 2/28/2014. PMCID: PMC4035022.
43. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G, Australian Cancer Study, Australian Ovarian Cancer Study Group, Lu Y, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Despierre E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Friel G, Moysich KB, Odunsi K, Sucheston-Campbell L, Lurie G, Goodman MT, Carney ME, Thompson PJ, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Nevanlinna H, Pelttari LM, Butzow R, Bunker CH, Modugno F, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Karlan BY, Walsh C, Lester J, Jensen A, Kjær SK, Høgdall CK, Høgdall E, Lundvall L, Sellers TA, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Giles GG, Baglietto L, Severi G, Southey MC, Liang D, Wu X, Lu K, Hildebrandt MA, Levine DA, Bisogna M, Schildkraut JM, Iversen ES, Weber RP, Berchuck A, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Chandran U, Orlow I, Olson SH, Wik E, Salvesen HB, Bjorge L, Halle MK, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Pejovic T, Bean YT, Cybulski C, Gronwald J, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Dicks E, Dennis J, Easton DF, Song H, Tyrer JP, Pharoah PD, Eccles D, Campbell IG, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Flanagan JM, Paul J, Brown R, Phelan CM, Risch HA, McLaughlin JR, Narod SA, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Gayther SA, Ramus SJ, Wu AH, Pearce CL, Pike MC, Dansonka-Mieszkowska A, Rzepecka IK, Szafron LM, Kupryjanczyk J, Cook LS, Le ND, Brooks-Wilson A, Ovarian Cancer Association Consortium. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet 133(5):481-97, 5/2014. e-Pub 11/5/2013. PMCID: PMC4063682.
44. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, Lu K, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res 34(5):2349-55, 5/2014. PMID: 24778042.
45. Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, Lu K, Miller D, Moore D, Petereit D, Schefter T, Small W, Yashar C, Viswanathan AN. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 4(3):137-44, May-Jun, 5/2014. e-Pub 3/31/2014. PMID: 24766678.
46. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer. Int J Gynecol Cancer 24(4):713-7, 5/2014. e-Pub 3/19/2014. PMCID: PMC4039301.
47. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, Lu K, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget 5(7):1846-55, 4/15/2014. PMCID: PMC4039109.
48. Daniels MS, Babb SA, King RH, Urbauer DL, Batte BA, Brandt AC, Amos CI, Buchanan AH, Mutch DG, Lu KH. Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study. J Clin Oncol 32(12):1249-55, 4/20/2014. e-Pub 3/17/2014. PMID: 24638001.
49. Zhang Q, Schmandt R, Celestino J, McCampbell A, Yates MS, Urbauer DL, Broaddus RR, Loose DS, Shipley GL, Lu KH. CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity. Gynecol Oncol 133(1):83-9, 4/2014. PMCID: PMC4077340.
50. Basen-Engquist K, Carmack C, Brown J, Jhingran A, Baum G, Song J, Scruggs S, Swartz MC, Cox MG, Lu KH. Response to an exercise intervention after endometrial cancer: Differences between obese and non-obese survivors. Gynecol Oncol 133(1):48-55, 4/2014. PMCID: PMC3979927.
51. Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, Kohlmann W, Lindor NM, Mulvey TM, Robinson L, Rubinstein WS, Stoffel EM, Snyder C, Syngal S, Merrill JK, Wollins DS, Hughes KS, American Society of Clinical Oncology. American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers. J Clin Oncol 32(8):833-40, 3/10/2014. e-Pub 2/3/2014. PMCID: PMC3940540.
52. Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, Neuss MN, Hughes KS. Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol 32(8):824-9, 3/10/2014. e-Pub 2/3/2014. PMID: 24493722.
53. Holman LL, Lu KH, Bast RC, Hernandez MA, Bodurka DC, Skates S, Sun CC. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol 210(3):257.e1-6, 3/2014. e-Pub 11/16/2013. PMCID: PMC4001707.
54. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeney LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G, for AOCS/ACS group, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dörk T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despierre E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL. Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. Cancer Res 74(3):852-61, 2/1/2014. e-Pub 11/22/2013. PMCID: PMC3946482.
55. Meng QH, Xu E, Hildebrandt MA, Liang D, Lu K, Ye Y, Wagar EA, Wu X. Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome. Clin Chem 60(1):222-32, 1/2014. e-Pub 10/21/2013. PMID: 24146310.
56. Bannon SA, Mork M, Vilar E, Peterson SK, Lu K, Lynch PM, Rodriguez-Bigas MA, You YN. Patient-reported disease knowledge and educational needs in Lynch syndrome: findings of an interactive multidisciplinary patient conference. Hered Cancer Clin Pract 12(1):1, 2014. e-Pub 2/5/2014. PMCID: PMC3922108.
57. Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, Lu KH, Luthra R, Broaddus RR. Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer. Curr Pharm Des 20(11):1655-63, 2014. e-Pub 7/19/2013. PMCID: PMC3895501.
58. Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J, Broaddus R, Hancock JF, Schmandt R, Lu KH. Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy. Mol Cancer Ther 12(12):2847-56, 12/2013. e-Pub 9/27/2013. PMCID: PMC3883498.
59. Daniels MS, Urbauer DL, Zangeneh A, Batte BA, Dempsey KM, Lu KH. Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist. Gynecol Oncol 131(3):619-23, 12/2013. e-Pub 10/17/2013. PMCID: PMC4123330.
60. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19):3454-61, 10/1/2013. e-Pub 8/26/2013. PMCID: PMC3982191.
61. Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G, GCIG Endometrial Cancer Clinical Trials Planning Meeting. Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking endometrial cancer trials into the translational era. Int J Gynecol Cancer 23(8):1528-34, 10/2013. PMID: 24257568.
62. Huang M, Djordejevic B, Yates MS, Urbauer D, Sun C, Burzawa J, Daniels M, Westin SN, Broaddus R, Lu K. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer 119(16):3027-33, 8/2013.
63. Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, Lynch H, Cornelison T, Boyd-Rogers S, Rubin M, Daniels MS, Conrad P, Milbourne A, Gershenson DM, Broaddus RR. Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome. Cancer Prev Res (Phila) 6(8):774-81, 8/2013. e-Pub 5/2/2013. PMCID: PMC3737517.
64. Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, Lu KH. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol 209(1):24.e1-24.e12, 7/2013. e-Pub 3/15/2013. PMCID: PMC3819145.
65. Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer 12(2):273-7, 6/2013. PMCID: PMC3820416.
66. Jhingran A, Ramondetta LM, Bodurka DC, Slomovitz BM, Brown J, Levy LB, Garcia ME, Eifel PJ, Lu KH, Burke TW. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol 129(2):304-9, 5/2013. e-Pub 2/4/2013. PMID: 23385150.
67. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated Breast Cancers. Breast J 19(1):87-91, Jan-Feb, 1/2013. e-Pub 12/10/2012. PMID: 23231005.
68. Shirvani SM, Klopp AH, Likhacheva A, Jhingran A, Soliman PT, Lu KH, Eifel PJ. Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer. Pract Radiat Oncol 3(1):e21-8, Jan-Mar, 1/2013. e-Pub 5/3/2012. PMID: 24674269.
69. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M, PRACTICAL Consortium, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Woo YL, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Weber RP, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Rossing MA, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Omar SZ, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubinski J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer SK, Kiemeney LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall CK, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Dürst M, du Bois A, Dörk T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA, Australian Ovarian Cancer Study Group, Australian Cancer Study, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, G. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 4:1628, 2013. PMCID: PMC3848248.
70. Wang Y, Ye Y, Lin J, Meyer L, Wu X, Lu K and Liang D. Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome. Mol Carcinog:doi: 10.1002/mc.22111, 2013.
71. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, kConFab Investigators, Radice P, Schmutzler RK, SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M, Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Toland AE, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT, HEBON, EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ, GEMO Study Collaborators, Zlowocka-Perlowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschm. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 9(3):e1003212, 2013. e-Pub 3/27/2013. PMCID: PMC3609646.
72. Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, Woodward WA, Lu K, Salimian B, Nagrath D, Klopp AH. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One 8(12):e81859, 2013. e-Pub 12/2/2013. PMCID: PMC3847080.
73. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Australian Cancer Study, Australian Ovarian Cancer Study, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Consortium of Investigators of Modifiers of BRCA1/2, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubinski J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, . Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 4:1627, 2013. PMCID: PMC3709460.
74. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107(10):1776-82, 11/6/2012. e-Pub 10/9/2012. PMCID: PMC3493866.
75. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22(11):2120-9, 11/2012. e-Pub 10/1/2012. PMCID: PMC3483541.
76. Pande M, Wei C, Chen J, Amos CI, Lynch PM, Lu KH, Lucio LA, Boyd-Rogers SG, Bannon SA, Mork ME, Frazier ML. Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry. Fam Cancer 11(3):441-7, 9/2012. e-Pub 6/20/2012. PMCID: PMC3475767.
77. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group Study. Cancer 118(12):3087-94, 6/15/2012. e-Pub 11/9/2011. PMID: 22072418.
78. Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB, Redding SW, Lu KH, Bast RC, McDevitt JT. Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Towards Ovarian Cancer Diagnostics at the Point-of-Care. Cancer Prev Res (Phila) 5(5):706-16, 5/2012. e-Pub 4/9/2012. PMCID: PMC3677577.
79. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol 206(4):351.e1-8, 4/2012. e-Pub 12/30/2011. PMCID: PMC3985608.
80. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 206(4):349.e1-7, 4/2012. e-Pub 12/30/2011. PMCID: PMC3987114.
81. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. J Clin Oncol 30(8):777-82, 3/10/2012. e-Pub 1/23/2012. PMCID: PMC3295566.
82. Wang LE, Ma H, Hale KS, Yin M, Meyer LA, Liu H, Li J, Lu KH, Hennessy BT, Li X, Spitz MR, Wei Q, Mills GB. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol 138(3):377-85, 3/2012. e-Pub 12/7/2011. PMCID: PMC3526101.
83. Klopp AH, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M, Debeb B, Woodward W, Schmandt R, Broaddus R, Lu K, Kolonin MG. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res 18(3):771-82, 2/1/2012. e-Pub 12/13/2011. PMID: 22167410.
84. Holman LL, Lu KH. Genetic risk and gynecologic cancers. Hematol Oncol Clin North Am 26(1):13-29, 2/2012. PMID: 22244659.
85. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 1/15/2012. e-Pub 9/12/2011. PMID: 21913181.
86. Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer 118(1):91-100, 1/1/2012. e-Pub 6/29/2011. PMCID: PMC3385508.
87. Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Higgins R, Zaino R, Mutter GL. Management of endometrial precancers. Obstet Gynecol 1220(5):160-1175, 2012. PMCID: PMCPMC800154.
88. Ready K, Arun BK, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 12/2011. e-Pub 6/17/2011. PMID: 21681553.
89. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 205(6):518-25, 12/2011. e-Pub 6/7/2011. PMCID: PMC4264838.
90. Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowtz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res 4(9):1401-8, 9/2011. PMID: 21893500.
91. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 122(3):548-53, 9/2011. e-Pub 6/25/2011. PMCID: PMC3152646.
92. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB. High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. Cancer Discov 1(2):170-185, 7/2011. e-Pub 6/7/2011. PMCID: PMC3187555.
93. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 117(12):2659-67, 6/15/2011. e-Pub 12/29/2010. PMCID: PMC4254830.
94. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing Women With Endometrial Cancer to Detect Lynch Syndrome. J Clin Oncol 29(16):2247-52, 6/1/2011. e-Pub 5/2/2011. PMID: 21537049.
95. Daniels MS, Burzawa JK, Brandt AC, Schmeler KM, Lu KH. A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges. Fam Cancer 10(2):193-7, 6/2011. e-Pub 1/2011. PMCID: PMC4286250.
96. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer. Am J Surg Pathol 35(6):904-12, 6/2011. e-Pub 3/2011. PMCID: PMC3095702.
97. Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121(2):358-63, 5/1/2011. e-Pub 1/28/2011. PMCID: PMC3310886.
98. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, Chang S, Gershenson DM, Brown J, Lu KH. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol 204(4):355.e1-7, 4/2011. e-Pub 2/16/2011. PMCID: PMC4286377.
99. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD, PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 4(3):375-83, 3/2011. PMCID: PMC3057372.
100. Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun B. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 17(2):210-2, 3/2011. e-Pub 2/7/2011. PMID: 21294809.
101. Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila) 4(3):463-70, 3/2011. e-Pub 1/28/2011. PMCID: PMC3048908.
102. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4(3):365-74, 3/2011. PMCID: PMC3085251.
103. Soliman PT, Cui X, Zhang Q, Hankinson SE, Lu KH. Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. Am J Obstet Gynecol 204(2):167.e1-5, 2/2011. e-Pub 11/3/2010. PMCID: PMC3032826.
104. Vineyard MA, Daniels MS, Urbauer DL, Deavers MT, Sun CC, Boerwinkle E, Bodurka DC, Gershenson DM, Crawford J, Lu KH. Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer? Gynecol Oncol 120(2):229-32, 2/2011. e-Pub 12/3/2010. PMID: 21126756.
105. Huang M, Sun C, Boyd-Rogers S, Burzawa J, Milbourne A, Keeler E, Yzquierdo R, Lynch P, Peterson SK, Lu K. Prospective study of combined colon and endometrial cancer screening in women with lynch syndrome: a patient-centered approach. J Oncol Pract 7(1):43-7, 1/2011. PMCID: PMC3014510.
106. Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, Chang DW, Meyer L, Wu X, Liang D. Genetic Variants in TGF-ß Pathway Are Associated with Ovarian Cancer Risk. PLoS One 6(9):e25559, 2011. e-Pub 9/2011. PMCID: PMC3184159.
107. Han CH, Huang YJ, Lu KH, Liu Z, Mills GB, Wei Q, Wang LE. Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. J Exp Clin Cancer Res 30(1):5, 2011. e-Pub 1/7/2011. PMCID: PMC3025876.
108. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 116(23):5415-9, 12/1/2010. e-Pub 8/2/2010. PMID: 20681032.
109. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, Lu K. Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response. Cancer Res 70(23):9765-76, 12/1/2010. e-Pub 11/30/2010. PMID: 21118967.
110. Nabilsi NH, Broaddus RR, McCampbell AS, Lu KH, Lynch HT, Chen LM, Loose DS. Sex hormone regulation of survivin gene expression. J Endocrinol 207(2):237-243, 11/2010. e-Pub 8/26/2010. PMCID: PMC4270120.
111. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dörk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC, Wellcome Trust Case-Control Consortium, Beesley J, Webb PM, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Ovarian Cancer Association Consortium (OCAC), Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Dürst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD, Ovarian Cancer Association Consortium (OCAC). A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42(10):874-9, 10/2010. e-Pub 9/19/2010. PMCID: PMC3020231.
112. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 177(4):1611-7, 10/2010. e-Pub 8/27/2010. PMCID: PMC2947258.
113. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214-20, 9/20/2010. e-Pub 8/23/2010. PMID: 20733129.
114. Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, Arun BK, Lu KH. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9(3):479-87, 9/2010. e-Pub 4/30/2010. PMID: 20431955.
115. Ready KJ, Daniels MS, Sun CC, Peterson SK, Northrup H, Lu KH. Obstetrics/Gynecology Residents' Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome. J Cancer Educ 25(3):401-4, 9/2010. e-Pub 2/26/2010. PMID: 20186516.
116. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB. Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer. J Clin Oncol 28(22):3570-6, 8/1/2010. e-Pub 7/6/2010. PMCID: PMC2917312.
117. Lu KH. Evaluating woment with ovarian cancer for BRCA1 and BRCA2 mutations: Missed opportunities. Obstet Gynecol 116(No. 2, Part 1):441, 8/2010.
118. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737):245-51, 7/24/2010. e-Pub 7/6/2010. PMID: 20609468.
119. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol 117(3):467-72, 6/2010. e-Pub 3/26/2010. PMCID: PMC2882061.
120. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28(13):2159-66, 5/1/2010. e-Pub 4/5/2010. PMCID: PMC2860434.
121. Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 115(5):945-52, 5/2010. PMID: 20410767.
122. Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing Future Cancers by Testing Women With Ovarian Cancer for BRCA Mutations. J Clin Oncol 28(4):675-82, 2/1/2010. e-Pub 10/19/2009. PMID: 19841329.
123. Schmeler KM, Daniels MS, Soliman PT, Broaddus RR, Deavers MT, Vu TM, Chang GJ, Lu KH. Primary Peritoneal Cancer After Bilateral Salpingo-Oophorectomy in Two Patients With Lynch Syndrome. Obstet Gynecol 115(2):432-4, 2/2010. PMCID: PMC4250042.
124. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214-4220, 2010. PMID: 20733129.
125. Zhang X, Zhang Q, Zhang J, Qiu L, Yan SS, Feng J, Sun Y, Huang X, Lu KH, Li Z. FATS is a transcriptional target of p53 and associated with antitumor activity. Mol Cancer 9:244, 2010. e-Pub 9/16/2010. PMCID: PMC2946289.
126. An J, Wei Q, Liu Z, Lu KH, Cheng X, Mills GB, Wang LE. Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. Int J Mol Epidemiol Genet 1(1):1-10, 2010. PMCID: PMC2916180.
127. Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, Lacour RA, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther 8(22):2126-35, 11/2009. e-Pub 11/2009. PMCID: PMC2872176.
128. Klopp AH, Jhingran A, Ramondetta L, Lu K, Gershenson DM, Eifel PJ. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol 115(1):6-11, 10/2009. e-Pub 7/25/2009. PMID: 19632709.
129. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 22(9):1243-50, 9/2009. e-Pub 6/12/2009. PMCID: PMC2736318.
130. Lu KH, Yates MS, Mok SC. The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention. Cancer Prev Res (Phila Pa) 2(9):773-5, 9/2009. e-Pub 9/2009. PMID: 19737981.
131. Daniels MS, Urbauer DL, Stanley JL, Johnson KG, Lu KH. Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer. Genet Med 11(9):624-8, 9/2009. e-Pub 7/14/2009. PMID: 19606053.
132. Schmeler KM, Daniels MS, Brandt AC, Lu KH. Endometrial cancer in an adolescent: a possible manifestation of Cowden Syndrome. Obstet Gynecol 114(2 Pt 2):1-7, 8/2009. PMID: 19622968.
133. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48-52, 7/2009. e-Pub 4/10/2009. PMID: 19361839.
134. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 4/15/2009. PMCID: PMC2680417.
135. Lu KH. Management of Early-Stage Endometrial Cancer. Semin Oncol 36(2):137-44, 4/2009. PMID: 19332248.
136. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 115(4):725-30, 2/15/2009. PMID: 19127556.
137. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, Lu KH. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol 200(2):186.e1-8, 2/2009. PMID: 19185100.
138. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 16(1):14-22, 1/2009. PMID: 19078925.
139. Basen-Engquist K, Scruggs S, Jhingran A, Bodurka DC, Lu K, Ramondetta L, Hughes D, Carmack Taylor C. Physical activity and obesity in endometrial cancer survivors: associations with pain , fatigue, and physical functioning. Am J Obstet Gynecol 200(3):288, 2009.
140. Soliman PT, Bassett RL, Wilson EB, Boyd-Rogers S, Schmeler KM, Milam MR, Gershenson DM, Lu KH. Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol 112(4):835-42, 10/2008. PMID: 18827126.
141. Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 111(1):132-6, 10/2008. e-Pub 8/6/2008. PMID: 18684498.
142. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, Lu KH. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch Syndrome. Cancer 113(2):326-35, 7/15/2008. PMID: 18506736.
143. Kwon JS, Lu KH. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women. Obstet Gynecol 112(1):56-63, 7/2008. PMID: 18591308.
144. Meyer LA, Westin SN, Lu KH, Milam MR. Genetic polymorphisms and endometrial cancer risk. Expert Rev Anticancer Ther 8(7):1159-67, 7/2008. PMID: 18588460.
145. Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl Oncol 10(6):313-7, 6/2008. PMID: 18558577.
146. Klopp AH, Jhingran A, Ramdas L, Story MD, Broadus RR, Lu KH, Eifel PJ, Buchholz TA. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys 71(1):226-36, 5/1/2008. PMID: 18406887.
147. Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 14(9):2543-50, 5/2008. PMID: 18451215.
148. Milam MR, Soliman PT, Chung LH, Schmeler KM, Bassett RL, Broaddus RR, Lu KH. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. Int J Gynecol Cancer 18(1):146-51, Jan-Feb, 1/2008. e-Pub 4/26/2007. PMID: 17466036.
149. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka D, Lu KH, Broaddus R. Carcinoma of the lower uterine segment: A newly described association with Lynch syndrome. J Clin Oncol 26(36):5965-71, 2008. e-Pub 11/2008. PMCID: PMC2645115.
150. Batista LI, Lu KH, Beahm EK, Arun BK, Bodurka DC, Meric-Bernstam F. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer 8:101, 2008. PMCID: PMC2362122.
151. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer 7(1):53-8, 2008. e-Pub 7/2007. PMID: 17636427.
152. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC Jr. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regularted in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112(7):1489-502, 2008.
153. Zhai J, Rosen DG, Lu K, Liu J. Loss of DNA mismatch repair gene hMLH6 in ovarian cancer is histotype specific. Int J Clin & Exp Pathol 1(6):502-9, 2008.
154. Wu W, Celestino J, Milam MR, Schmeler KM, Broaddus RR, Ellenson LH, Lu KH. Primary chemocprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. Int J Gynecol Cancer 18(2):529-38, 2008.
155. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC JR, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110(2):196-201, 2008.
156. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol 107:58-65, 7/2007. PMCID: PMCOMC2777971.
157. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer 7(1):53-8, 7/2007.
158. Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B. BRCA1 and BRCA2 genetics testing in hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25(29):4635-41, 2007.
159. Shvartsman HS, Sun CC, Bodurka DC, Majajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 105:625-9, 2007.
160. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E associated kinase activity predicts response to platinum based chemotherapy. Clin Cancer Res 13:4800-6, 2007.
161. Lu KH, Kauff ND. Does a BRCA mutation plus tamoxifen equal hysterectomy? Gynecol Oncol 104(1):3-4, 2007. PMID: 17222708.
162. Soliman PT, Lu K. Endometrial cancer associated with defective DNA mismatch repair. Obstet Gynecol Clin North Am 34:701-15, 2007.
163. Saldivar JS, Lu KH, Liang D, Gu J, Hunang M, Vlastos AT, Follen M, Wu X. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 107:S223-9, 2007.
164. Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer: mission impossible? Cancer Res 174:91-100, 2007.
165. Lu K, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of Lynch Syndrome in young women with endometrial cancer. J Clin Oncol 25:58-64, 2007.
166. Milam MR, Celestino J, Wu W, Broaddus RR, Slomovitz BM, Schmeler KM, Soliman PT, Gershenson DM, Wang H, Ellsenson LH, Lu KH. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the PTEN heterozygote murine model. Am J Obstet Gynecol 196:247.el-247.el-5, 2007.
167. Wong KK, Lu KH. Significantly higher expression of ER, PR and ECAD in advanaced-stage low-grade ovarian serous carcinomas as revealed by immunohistochemical analysis. Intl J of Gynecol Pathol 26(4):404-9, 2007.
168. Lancaster JM, Bethan Powell C, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ: Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107:159-62, 2007.
169. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz IB, Lacour RA, Westin SN, Gershenson DM, Wu X, Lu K. STK15 F3II Polymorphism is associated with increased uterine cancer risk: A pilot study. Gynecol Oncol 107:71-4, 2007.
170. Milam MR, Sood AK, King S, Bassett RL, Lu KH, Slomovitz BM, Coleman RL. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet & Gynecol 109:641-6, 2007.
171. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 106:490-7, 2007.
172. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM, Pearson HC, Berenson A, Ramirez PT, Lu KH, Bodurka DC. Are women ready for the HPV vaccine? Gynecol Oncol 103:151-4, 2006. PMID: 16551476.
173. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM, Lu KH. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 106:2376-81, 2006. PMID: 16639730.
174. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107:2745-51, 2006. PMID: 17109443.
175. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108:361-8, 2006. PMID: 16880307.
176. Wu W, Slomovitz BM, Soliman PT, Schmeler KM, Celestino J, Milam MR, Lu KH. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. Int J Gynecol Cancer 16:1668-72, 2006. PMID: 16884382.
177. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkins SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 66:1182-90, 2006.
178. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Jr, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 66:2740-8, 2006. PMID: 16510595.
179. Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, White KG, Luthra R, Lu KH. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106:87-94, 2006. PMID: 16323174.
180. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12:3661-97, 2006. PMID: 16778094.
181. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations. Obstet Gynecol 108:515-520, 2006. PMID: 16946209.
182. Schmeler K, Lynch H, Chen L, Munsell M, Soliman P, Clark M, White K, Boyd-Rogers S, Conrad P, Yang K, Rubin M, Sun C, Slomovitz B, Gershenson D, Lu K. Prophylactic surgery for the reduction of gynecologic cancer risk in women with Lynch Syndrome (HNPCC). N Eng J of Med 354:261-9, 2006.
183. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu K, Lynch P, Burke W, Press N. Recommendations for the care of individuals with an inherited predisposition to cancer: Hereditary nonpolyposis colorectal cancer (Lynch Syndrome). JAMA 296:1507-17, 2006.
184. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther 5:1136-41, 2006. PMID: 16855388.
185. Broaddus RR, Lu KH. Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. Front Biosci 11:2077-80, 2006. PMID: 16720294.
186. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102:12519-24, 2005. PMID: 16116079.
187. Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol 99:388-92, 2005. PMID: 16051336.
188. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65:10602-12, 2005. PMID: 16288054.
189. Broaddus RR, Lu KH. Future challenges in clinical and translational research for endometrial cancer. Int J Gyn Cancer 15:398, 2005.
190. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11:2149-55, 2005. PMID: 15788660.
191. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105:569-74, 2005. PMID: 15738026.
192. Lu, K, Broaddus R. Gynecologic cancers in Lynch Syndrome/HNPCC. Familial Cancer 4:249-254, 2005.
193. Slomovitz BM, Ramondetta LM, Lee CM, Oh JC, Eifel PJ, Jhingran A, Burke TW, Gershenson DM, Lu KH. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer 15:510-6, 2005. PMID: 15882178.
194. Caudell JJ, Deavers MT, Slomovitz BM, Lu KH, Broaddus RR, Gershenson DM, Ramondetta LM. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol 13:167-70, 2005. PMID: 15894930.
195. Cheng YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica 90:1725-6, 2005. PMID: 16330461.
196. Liu Z, Wang LE, Wang L, Lu KH, Mills GB, Bondy ML, Wei Q. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res 11:4968-76, 2005. PMID: 16000597.
197. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA126 and beyond. Int J Gynl Cancer 3:274-81, 2005.
198. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Jr, Lu KH. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11:6116-26, 2005. PMID: 16144910.
199. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC, Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267-77, 2005. PMID: 16061277.
200. Lee CM, Slomovitz BM, Greer M, Sharma S, Gregurich MA, Burke T, Lu KH, Ramondetta LM. Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecol Oncol 98:77-83, 2005. PMID: 15907988.
201. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 105:575-80, 2005. PMID: 15738027.
202. Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med 50:417-25, 2005. PMID: 16050566.
203. Soliman PT, Broaddus RR, Schmeler KM, Daniels MS, Gonzalez D, Slomovitz BM, Gershenson DM, Lu KH. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol 23:9344-50, 2005. PMID: 16361634.
204. Vidal CI, Mintz PJ, Lu K, Ellis LM, Manenti L, Giavazzi R, Gershenson D, Broaddus R, Liu J, Arap W, Pasqualini R. An HSP90-minmic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene 23:8859-67, 2004.
205. Slomovitz BM, Lu KH. Commenting on "HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (88:263-5) by Santin AD". Gynecol Oncol 92:386-7; author reply 387, 2004. PMID: 14751194.
206. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 23:2648-57, 2004. PMID: 15007381.
207. Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol 104:255-60, 2004. PMID: 15291996.
208. Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol 95:32-6, 2004. PMID: 15385107.
209. Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC, Jr. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 10:6559-66, 2004. PMID: 15475444.
210. Malpica, A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Path 28:496-504, 2004.
211. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22:3126-32, 2004. PMID: 15284264.
212. Oh JC, Wu W, Tortolero-Luna G, Broaddus R, Gershenson DM, Burke TW, Schmandt R, Lu KH. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 13:748-52, 2004. PMID: 15159305.
213. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC, Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10:3291-300, 2004. PMID: 15161682.
214. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94:456-62, 2004. PMID: 15297188.
215. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10:1251-6, 2004. PMID: 15502842.
216. Broaddus RR, Lynch PM, Lu KH, Luthra R, Michelson SJ. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol 17:981-9, 2004. PMID: 15143336.
217. Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu KH. beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 88:363-8, 2003. PMID: 12648588.
218. Slomovitz BM, Burke TW, Oh J, Broaddus RR, Eifel PJ, Atkinson EN, Silva EG, Gershenson DM, Lu KH. Clinical and pathologic characteristics of uterine papillary serous carcinoma (UPSC): A single institution review of 129 cases. Gynecologic Oncology 91:463-69, 2003.
219. Wu W, Slomovitz BM, Celestino J, Chung L, Thornton A, Lu KH. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res 63:6195-9, 2003. PMID: 14559803.
220. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98:758-64, 2003. PMID: 12910520.
221. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9:4782-91, 2003. PMID: 14581349.
222. Jazaeri A, Lu K, Schmandt R, Harris C, Rao P, Chandramouli G, Gershenson D, Liu E. Molecular Determinants of Tumor Differentiation in Papillary Serous Ovarian Carcinoma. Molecular Carcinogenesis 36:53-59, 2003.
223. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Jr, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90:44-50, 2003. PMID: 12821340.
224. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JW, Berchuck A, Lu K, Smith D, Kimberly K, Hartmann L, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GR. Role of decreased levels of LLP-1 in accumulation of lysophosphatidic acid (LPA) in ovarian cancer. Clinical Cancer Research 9:3534-3545, 2003.
225. Chung L, Broaddus R, Crozier M, Luthra R, Levenback C, Lu K. Unexpected Endometrial Cancer at Prophylactic Hysterectomy in a Woman with HNPCC. . Obstetrics & Gynecology 102:1152-1155, 2003.
226. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91:463-9, 2003. PMID: 14675663.
227. Bast Jr RC, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: Promise and reality. Cancer Treat Res 107:61-97, 2002. PMID: 11775462.
228. Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol 26:1129-41, 2002. PMID: 12218569.
229. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA, Chu C, Stehman FB, van Nagell J. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 87:1-7, 2002. PMID: 12468335.
230. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstetrics & Gynecolog 99:3-10, 2002.
231. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC, Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Research 61:5895-904, 2001.
232. Lu KH, Broaddus RR. Gynecological tumors in hereditary nonpolyposis colorectal cancer: We know they are common-now what? Gynecol Oncol 82:221-2, 2001. PMID: 11531270.
233. Azevedo P, Verschraegen, CF, Kavanagh JJ, Kudelka AP, Freedman RS, Lu K, Deavers MT. Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. European Journal of Gynaecological Oncology 22:319-21, 2001.
234. Suzuki ,S, Moore DH, 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Research 60:5382-5, 2000.
235. Lu KH, Burke TW. Early cervical cancer. Curr Treat Options Oncol 1:147-55, 2000. PMID: 12057052.
236. Hoyte L, Lu K, Muto M, Nucci M, Versi E, Kikinis R, Fielding J. Magnetic resonance impaging based three dimensional modeling of a comple vulvar tumor as a component of presurgical planning. Journal of Women's Imaging: 2:138-40, 2000.
237. Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18:2728-32, 2000. PMID: 10894872.
238. Tuncer ZS, Bernstein MR, Goldstein DP, Lu KH, Berkowitz RS. Outcome of pregnancies occurring within 1 year of hydatidiform mole. Obstet Gynecol 94(4):588-90, 10/1999. PMID: 10511364.
239. Garner EI, Chang-Lee WY, Lu KH, Goldstein DP, Berkowitz RS. Trophoblastic pulmonary embolization after hysterectomy for invasive complete mole. A case report. J Reprod Med 44(10):908-12, 10/1999. PMID: 10554759.
240. Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 93(1):34-7, 1/1999. PMID: 9916952.
241. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 58(11):2328-30, 6/1/1998. PMID: 9622067.
242. Lu KH, Weitzel JN, Kodali S, Welch WR, Berkowitz RS, Mok SC. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res 57(3):387-90, 2/1/1997. PMID: 9012461.
243. Williams DA, Hsieh K, DeSilva A, Mulligan RC. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med 166:210-8, 1987. PMID: 3298524.

Invited Articles

1. Lu KH. "Best Health", Endometrial Cancer Related Links. U.S. News & World Report, 1/2007.
2. Lu KH. Update in Gynecologic Cancer. OBG Management, 2007.
3. Lu KH. Update in Gynecologic Cancer. OBG Management, 2006.
4. Lu KH. Update in Gynecologic Cancer. OBG Management, 2005.
5. Lu KH. More Communication Needed to Address Gyn Cancer Risks in Breast Cancer Patients. . MAMM(July/August):p 19, 2003.
6. Lu KH. The Levine/Gemignami Article Reviewed (Prophylactic Surgery in Hereditary Breast/Ovarian Cancer Syndrome). Oncology 17:951-952, 2003.
7. Lu KH, Burke TW. Early cervical cancer. Current Treatment Options in Oncology 1(2):147-55, 6/2000.
8. Lu KH, Gershenson DM. Management of borderline ovarian tumors. Contemporary OB/GYN 45:89-100, 2000.
9. Lu KH, Goldstein DP, Bernstein MR, Berkowitz RS. Clinical decisions in gestational trophoblastic diseases. Contemporary OB/GYN, 1999.
10. Lu KH, Goldstein DP, Bernstein MR, Berkowitz RS. Managing molar pregnancies. OBG Management, 1999.
11. Lu KH, Edelson MI, Rodabaugh KJ, Wertheim I, Colitti CV, Bell DA, Welch WR, Berkowitz RS, Mok SC. Pathogenesis of borderline ovarian tumors. Proc AACR 40:760-761, 1999.

Editorials

1. Daniels MS, Lu KH. Reply to D. Braun et al. J Clin Oncol 32(32):3683, 11/10/2014. e-Pub 9/8/2014. PMID: 25199758.
2. Wood ME, Lu KH, Wollins DS, Hughes KS. Reply to A.S. Sie et al, K. Hemminki et al, and J. Larsen Haidle. J Clin Oncol 32(29):3346-7, 10/10/2014. e-Pub 9/2/2014. PMID: 25185101.
3. Lu KH, Kauff ND. Does a BRCA mutation plus tamoxifen equal hysterectomy? Gynecol Oncol 104(1)(1):3-4, 1/2007. PMID: 17222708.
4. Lu KH. Gynecologic tumors in hereditary nonpolyposis colorectal cancer: We know they are common-now what? Gynecologic Oncology 82:221-2, 2001.
Other Articles
1. Lu, KH, JE Garber, DW Cramer, WR Welch, J Niloff, D Schrag, RS Berkowitz, M G Muto. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. Journal of Clinical Oncology/Classic Papers and Current Comments 18(14):2728-2732, 2000.

Abstracts

1. Holman L, Friedman S, Daniels M, Sun C, Lu K. Acceptability of salpingectomy alone as risk-reducing surgery for BRCA mutation carriers. Proceedings of the 44th Annual Meeting of the Society of Gynecologic Oncology, 3/2013.
2. Ring K, Boyd-Rogers S, Amin Y, Daniels M, Batte B, Schmeler K, Keeler E, Lu K. Endometrial Cancer screening in Lynch syndrome: Do patients report symptoms prior to diagnosis?. Proceedings of the 44th Annual Meeting of the Society of Gynecologic Oncology, 3/2013.
3. Holman L, Soliman P, Pal N, Balakrishnan N, Klopp A, Broaddus R, Fleming N, Munsell M, Lu K, Westin S. Importance of platinum sensitivity and treatment modality in advanced-stage uterine papillary serous carcinoma. Proceedings of the 44th Annual Meeting of the Society of Gynecologic Oncology, 3/2013.
4. Holma L, Soliman P, Pal N, Mhadgut H, Klopp A, Boaddus R, Fleming N, Munsell M, Lu K, Westin S. Neoadjuvant chemotherapy in stage IV uterine papillary serous carcinoma. Proceedings of the 44th Annual Meeting of the Society of Gynecologic Oncology, 3/2013.
5. Ring , Daniels M, Batte B, Lu K. When you hear hoof beats, don't forget the zebra: The role of nonserous ovarian cancer in BRCA mutation carriers. Proceedings of the 44th Annual Meeting of the Society of Gynecologic Oncology, 3/2013.
6. Westin S, Sun C, Pal N, Janku F, Tsimberidou A, Falchook G, Hong D, Lu K, Coleman R, Kurzrock R. KRAS mutation in endometrial and ovarian cancers: Preliminary data on association with phenotype and clinical outcome in primary disease. Proceedings of the 44th Annual Meeting of the Society of Gynecologic Oncology, 2/2013.
7. Meyer L, Slomovitz B, Djordjevic B, Iglesias D, Westin S, Broaddus R, Munsell M, Wolf J, Gershenson D, Lu K. Can negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial cancer. Proceedings of the 43rd Annual Meeting of the Society of Gynecologic Oncology 125(1):#400, 3/2012.
8. Co N, Iglesias D, Schmandt R, Lu K. LKB1, a novel transcriptional target of p53, is down-regulated in high-grade endometrial carcinoma. Proceedings of the 43rd Annual Meeting of the Society of Gynecologic Oncology 125(1):#338, 3/2012.
9. Holman L, Lu K, Hernandez M, Bast R, Bodurka D, Skates S, Gershenson D, Sun C. Perception of risk, cancer worry, anxiety, and acceptability of screening among low-risk women undergoing ovarian cancer screening with the risk of ovarian cancer algorithm. Proceedings of the 43rd Annual Meeting of the Society of Gynecologic Oncology 125(1):#280, 3/2012.
10. Iglesias D, Burzawa J, Zhang Q, Co N, Celestino J, Yates M, Gershenson D, Schmandt R, Lu K. Pre-clinical in vitro and in vivo evidence to support personalized biologic treatment of endometrial cancer with metformin and P13K pathway inhibitors. Proceedings of the 43rd Annual Meeting of the Society of Gynecologic Oncology 125(1):#330, 3/2012.
11. Westin S, Sun C, Broaddus R, Pal N, Nath V, Urbauer D, Schmeler K, Lu K, Bodurka D, Johnston T. Prospective phase II trial of the Levonorgestrel Intrauterine System (Mirena) to treat complex atypical hyperplasia and grade 1 endometroid endometrial cancer. Proceedings of the 43rd Annual Meeting of the Society of Gynecologic Oncology 125(1):#15, 3/2012.
12. Meyer L, Liang D, Lin J, Ye Y, Huant M, Pu X, Lu K, Wu X. Genetic variants in the mammalian target of rapamycin (mTOR) signaling pathway as predictors of clinical response and survival in women with ovarian cancer. Gynecologic Oncology 120(1(1)):#51, March 2011, 3/2011.
13. Iglesias D, Sun C, Langstraat C, Bakkum-Gamez, El-Nashar S, Keeler E, Gershenson D, Lu K. Management and clinical outcomes of women with BRCA 1/2 mutations found to have occult cancers at the time of risk-reducing salpingo-oophorectomy. Gynecologic Oncology 120(1(1)):#137, March 2011, 3/2011.
14. Zhang Z, Skates SJ, Sokoll LJ, Lu Z, Clarke CH, Hernandez MA, Lu KH, Bast RC. A multivariate longitudinal algorithm for early detection of ovarian cancer using multiple biomarkers. Proceedings of the 2011 ASCO Annual Meeting 29:#5031, 2011.
15. Slomovitz BM, Brown J, Johnston TA, Mura D, Levenback C, Wolf J, Adler KR, Lu KH, Coleman RL. A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. Proceedings of the 2011 ASCO Annual Meeting 29:#5012, 2011.
16. Meyer LA, Slomovitz BM, Djordjevic B, Galbincea JM, Johnston TA, Munsell M, Burzawa JK, Huang M, Broaddus R, Iglesias DA, Coleman RL, Gershenson DM, Burke TW, Wolf J, Lu KH. The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. Proceedings of the 2011 ASCO Annual Meeting 29:#5016, 2011.
17. Jhingran A, Lu KH, Ramondetta LM, Burke TW, Wolf JK, Bodurka D, Brown J, Eifel PJ. A Prospective Phase II Study of Chemoradiation Followed by Adjuvant Chemotherapy for Stage I-IIIA Uterine Papillary Serous Carcinoma. Presented at SGO 41st Annual Meeting on Women's Cancer in San Francisco, CA, 2010.
18. Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L, Harris S, Adeyinka OW, Fritsche HA, Base RC. A Prospective U.S. Ovarian Cancer Screening Study Using the Risk of Ovarian Cancer Algorithm (ROCA). J Clin Oncol 28:15a, 2010.
19. Westin SN, Sun CC, Soliman PT, Lacour RA, Tung CS, Schlumbrecht MP, Meyer LA, Lu KH. Persistent Obesity Among Endometrial Cancer Survivors: A Teachable Moment?. Presented at the SGO 41st Annual Meeting on Women's Cancer in San Francisco, CA, 2010.
20. Sun CC, Peterson SK, White K, Watts B, Daniels M, Boyd-Rogers S, Schmeler K, Bodurka DC, Lu KH. Patient Preferences for Risk Management Strategies in Women with Lynch Syndrome. InSiGHT Annual Meeting 2009, Dusseldorf, Germany, 6/2009.
21. Hennessy B, Timms K, Carey MS, Gutin A, Broaddus R, Gonzalez-Angulo A, Lanchbury J, Lu K, Mills GB. Somatic BRCA status in ovarian tumors. J of Clin Oncol 27(158):284s, 5/2009.
22. Meyer LA, Anderson ME, Lacour RA, Westin SN, Burzawa JK, Urbauer DL, Daniels MS, Burke CC, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: A trend over time. Gynecol Oncol 112(2/1):S96-S07, 2009.
23. Burke CC, Meyer LA, Daniels MS, Schmeler KM, Garcia EA, Zook SU, Zalun G, Sam AV, Rothe ER, Anderson ME, Gershenson DM, Lu KH. Identification of women with ovarian cancer at risk for BRCA 1/2 mutations: Initial results from a quality improvement initiative. Gynecol Oncol 112(2/1):S20, 2009.
24. Kwon JS, Daniels MS, Sun CC, Lu KH. Opportunities for future cancer prevention by BRCA mutation testing of women with ovarian cancer. Gynecol Oncol 112(2/1):S98, 2009.
25. Westin SN, Lu KH, Lacour RA, Milam MR, Urbauer DL, Munsell MK, Loose DS, Broaddus RR. Proposed molecular diagnostic panel to guide decision making in endometrial cancer. Gynecol Oncol 112(2/1):S84-S85, 2009.
26. Burzawa JK, Schmeler KM, Soliman PT, Lacour RA, Meyer LA, Bevers MW, Fromovitz MM, Pustilnik TB, Brown J, Anderson ML, Ramondetta LM, Tortolero-Luna G, Gershenson DM, Lu KH. Prospective, populations-based evaluation of insulin resistance, polycystic ovary syndrome and metabolic syndrome in a cohort of patients with endometrial cancer. Gynecol Oncol 112(2/1):S85, 2009.
27. Westin SN, Lu KH, Milam MR, Lacour RA, Meyer LA, Urbauer DL, Bodurka DC, Broaddus RR. Adenocarcinoma of the lower uterine segment: A dinstinct clinical entity associated with Lynch syndrome. Gynecol Oncol 108(3(1)):S64-S65, 3/2008.
28. Wong KK, Tung C, Yeung CS, Zu Z, Tsang YT, Deavers M, Wolf J, Lu K, Birrer M, Mok SC, Gershenson DM. Decrease in the expression of BCMP11 during progression from low-malignant-potential to low-grade ovarian serous carcinoma. Gynecol Oncol 108(3(1)):s51, 3/2008.
29. Lacour RA, Daniels MS, Westin SN, Meyer LA, Choubey V, Blank SV, MacDonald HR, Roman L, Estes JM, Barnes M, Teoh D, Powell B, Sun cc, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Do BRCA mutations confer a survival advantage in all cases of advanced-stage ovarian cancer?. Gyecol Oncol 108(3(1)):S108S109, 3/2008.
30. Meyer LA, Westin SN, Lacour RA, Urbauer DL, Sun CC, Daniels MS, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1/2:missed opportunities. Gynecol Oncol 108(3(1)):S67, 3/2008.
31. Elmasry K, Ramus S, Whittaker J, Luo Z, Gammerman A, Lu K, Ayhan A, Singh N, McGluggage G, Jacobs I, Gayther S. Genetic diagnosis and clinical outcome n patients with synchronous ovarian and endometrial cancer. Gynecol Oncol 108(3(1)):S65, 3/2008.
32. Westin SN, Lu KH, Lacour RA, Meyer LA, Zie S, Urbauer DL, Broaddus RR. GRP78 has unique expression in normal endometrium and endometrial carcinoma. Gynecol Oncol 108(3(1)):S74, 3/2008.
33. Clarke CH, Fung ET, Yip C, Badgwell D, Joy C, Combes K, Lu K, Bast RC. Proteomic markers increase CA125 sensitivity for early detection of epithelial ovarian cancer. Gynecol Oncol 108(3(1)):S36, 3/2008.
34. Gershenson DM, Sun C, Bodurka D, Coleman RL, Lu KH, Sood AK, Kavanagh JJ. Recurrent low-grade serous carcinoma of the ovary is relatively chemoresistant. Gynecol Oncol 108(3(1)):S5, 3/2008.
35. Tung CS, Yeung C, Mok SC, Birrer MJ, Lu KH, Gershenson DM, Wong K. The role of PAX2 as a potential biomarker of low-grade serous ovarian carcinoma. Gynecol Oncol 108(3(1)):S57, 3/2008.
36. Sun SS, Peterson S, Lu KH, White K, Daniels M, Boyd-Rogers S, Westin SN, Bodurka DC. Women's preferences for cancer screening strategies and prophylactic surgery. Gynecol Oncol 108(3(1)):S137, 3/2008.
37. Slomovitz BM, Lu KH, Johnston T, Munsell M, Ramondetta LM, Broaddus RR, Coleman RL, Walker C, Gershenson DM, Burke TW, Wolf J. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC). J of Clin Oncol 26(15S):293s, 2008.
38. Lacour RA, Westin SN, Meyer LA, Soliman PT, Keeler ER, Boyd-Rogers SG, Urbauer DL, Broaddus RR, Loose DS, Lu KH. Alterations in estrogen-associated proliferation markers in histologically-normal endometrium of obese women. J of Clin Oncol 26(15S):684s, 2008.
39. Ready KJ, Gutierrez-Barrera AM, Atchley D, Solomon KK, Amos C, Meric-Bernstam F, Lu KH, Hortobagyi GN, Arun B. Cancer risk management decisions of women with BRCA variants of uncertain significance. J of Clin Oncol 26(15S):750s, 2008.
40. Meyer L, Westin SN, Lacour RA, Urbauer DL, Schmeler, KM, Daniels MS, Sun CC, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1/2: Missed opportunities. J of Clin Oncol 26(15S):300s, 2008.
41. Sun CC, Westin SN, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz MM, Gershenson DM, Lu KH, Bodurka DC. Health concerns of long-term survivors of gynecologic cancers. J of Clin Oncol 26(15S):727s, 2008.
42. Westin SN, Sun CC, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz MM, Lu KH, Gershenson DM, Bodurka DC. Survivors of gynecologic malignancies (GYN CA): Impact of treatment on health and well-being. J of Clin Oncol 26(15S):299s, 2008.
43. Clarke CH, Fung T, Yip C, Joy C, Badgwell D, Coombes KR, Zhang Z, Lu KH, Bast RC. Use of a panel of proteomic markers to improve the sensitivity of CA125 for detecting stage I epithelial ovarian cancer. J of Clin Oncol 26(15S):303s, 2008.
44. Skates SJ, Drescher CW, Isaacs C, Schildkraut JM, Armstrong DK, Buys SS, Brewster WR, Daly MB, Findelstein DM, Lu KH, ROCA Screening Study Group. A prospective multi-center ovarian cancer screening study in women at increased risk. Proceedings of the American Society of Clinical Oncologists 43rd Annual Meeting 25:5510, 2007.
45. de Souza JA, Wei C, Noguchi S, Lu K, Ishihara H, Aoki D, Ueno NT. Cyclin-dependent kinase (CDK) activity as a prognostic marker in primary epithelial ovarian cancer. Proceedings of the American Society of Clinical Oncology 43rd Annual Meeting 25:#5575, 2007.
46. Maxwell GL, Yurkovetsky Z, Lu K, Lisovich A, Linkov F, Lokshin AE. Development of multimarker panel for early detection of endometrial cancer: High diagnostic power of prolactin. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologist:#287, 2007.
47. Westin SN, Broaddus RR, Lu KH, Lacour RA, Milam MR, Urbauer DL, Nogueras GM, Nabilsi NH, Loose DS. Estrogen-regulated genes in endometrial cancer. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologists:#310, 2007.
48. Basen-Enquist K, Lenihan D, Carmack Taylor C, Lu K, Perkins H, Hughes D, McFalls K, Shin K. Fitness and quality of life in endometrial cancer survivors and controls. Proceedings of the American Society of Clinical Oncology 43rd Annual Meeting 25:#19502, 2007.
49. Wong KK, Tsang YTM, Gu Y, Lu KH, Deavers MT, Malpica A, Gershenson DM. High-resolution global genomic analysis of low-grade serous ovarian tumors reveals novel regions of allelic imbalances. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologists:#102, 2007.
50. Sun CC, Westin SN, Lu KH, Schmeler KM, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Impact of BRCA 1/2 testing: Body image, sexual functioning, and quality of life (QOL). Proceedings of the American Society of Clinical Oncologists 43rd Annual Meeting 25:#1525, 2007.
51. Soliman PT, Bassett RL, Boyd-Rogers S, Schmeler KM, Slomovitz BM, Gershenson DM, Lu KH. Knowledge of weight and endometrial cancer risk: What women know. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologists:#231, 2007.
52. Slomovitz BM, Burke T, Lu KH, Wolf J, Johnston T, Wu W, Cleestino J, Schmeler K, Soliman P, Broaddus R, Walker C. Loss of PTEN expression associated with response to RAD001 (mTOR inhibitor) in patients with recurrent endometrial cancer: Translational evaluation from a phase II study. Proceedings of the 38th Annual Meeting of the Society of Gynecolgoic Oncologists:#70, 2007.
53. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, White KG, Daniels NS, Arun BK, Peterson SK, Bodurka DC. Management strategies for women at high risk for breast and ovarian cancer: Are women satisfied?. Proceedings of the American Society of Clinical Oncology 43rd Annual Meeting 25:#1524, 2007.
54. Lacour RA, Urbauer DL, Nongueras-Gonzalez GM, Lu KH, Westin SN, Milam MR, Loose DS, Soliman PT, Schmeler KM, Wu W, Broaddus RR, Nabilsi NH. Molecular abnormalities in histologically normal endometrium of obese women. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologists:#67, 2007.
55. Milam MR, Sun CC, Landen CN, Schmeler KM, Lu KH, Coleman RL, Ramirez PT. Neoadjuvant chemotherapy improves perioperative outcomes in patients with advanced epithelial ovarian cancer. Proceedings of the 38th Annual Society of Gynecologic Oncologist Meeting:#160, 2007.
56. Burke TW, Navo MA, Smith JA, Jung MS, Broaddus R, Iyer RB, Lu KH, Sun CC, Atkinson EN, Ramondetta LM. Phase II trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinomas or low-grade endometrial stromal sarcoma (LGESS). Proceedings of the American Society of Clinical Oncologists 43rd Annual Meeting 25:#5595, 2007.
57. Lu K, Loose D, Lynch H, Lee-May C, Boyd-Rogers S, Rubin M, Daniels M, Blanco AM, Conrad P, White K, Munsell M, Broaddus R. Preliminary analysis of a prospective, multi-center endometrial cancer chemoprevention study in women with Lynch Syndrome. Proceedings of the 2nd Biennial Scientific Meeting of International Society of Gastrointestinal Hereditary Tumours (InSiGHT, Japan) March, 2007.
58. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz I, Lacour RA, Westin SN, Gershenson DM, Wu X, Lu KH. STK15 F311 polymorphisms and uterine cancer risk: A case-control analysis. Proceedings of the American Society of Clinical Oncologist 43rd Annual Meeting 25:5511, 2007.
59. Lacour RA, Westin SN, Daniels MS, Milam MR, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Survival in advanced-stage ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations. Proceedings of the American Society of Clinical Oncologist 43rd Annual Meeting 25:#5514, 2007.
60. Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Verch T, Lu KH, Allard JW, Granai CO, Bast R. A novel multiple biomarker assay for the detection of ovarian carcinoma. Proceedings of the American Society of Clinical Oncologists 42nd Annual Meeting 24:5023, 2006.
61. Schmeler K, Sun C, Bodurka DC, White K, Soliman PT, Uyei AR, Erlichman J, Arun B, Peterson S, Milam M, Slomovitz B, Gershenson DM, Lu K. Are women with BRCA1/2 mutations choosing prophylactic bilateral salpingo-oophorectomy over surveillance?. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #245:S107, 2006.
62. Schmandt R, Bennett M, Clifford S, Thornton A, Broaddus R, Jiang F, Lu K, Sood AK, Gershenson DM, Gray J. BRK/PTK6 is frequently amplified and promotes tumor growth in ovarian carcinoma. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #228:S99, 2006.
63. Uyei AR, Broglio KR, Solomon TL, Vogel KJ, Amos DI, Lu K, Meric-Bernstam F, Strong L, Arun B. Clinical factors that affect breast cancer risk reduction decisions in high risk women tested for the BRCA 1/2 genetic mutation. Proceedings of the American Society of Clinical Oncologists 42nd Annual Meeting 24:#1013, 2006.
64. Milam M, Slomovitz B, Schmeler K, Soliman PT, Ramirez P, Sun C, Eifel P, Ramondetta L, Lu K. Management and patterns of recurrence of women with occult stage II endometrioid endometrial cancer. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #413:S177, 2006.
65. Slomovitz B, Lu K, Burke TW, Soliman PT, Schmeler K, Munsell M, Johnston T, Coleman R, Ramondetter L, Gershenson DM, Solf J. mTOR is a rational target for the treatment of endometrial cancer: Preliminary results of a phase II study of RAD001 for patients with recurrent endometrial cancer. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #253:S110, 2006.
66. Schmeler K, Broaddus R, Sun C, Soliman PT, Milam M, Thornton A, Wu W, Slomovitz B, Gershenson DM, Lu K, McCampbell A, Shipley G. Obesity related endometrial cancers are not molecularly distinct from endometrial cancers arising in normal weight women. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #233:S101, 2006.
67. Sun CC, Peterson SK, White KG, Watts BG, Daniels MS, Boyd-Rogers SG, Schmeler KM, Bodurka DC, Lu KH. Preferences for cancer prevention strategies (CPS) in women with hereditary nonpolyposis colorectal cancer (HNPCC). Proceedings of the American Society of Clinical Oncologists 42nd Annual Meeting 24:#1018, 2006.
68. Schmeler K, Tortolero-Luna G, Soliman PT, Sun C, Milam M, Slomovitz B, Gershenson D, Lu K, Williams M, Betts P. Racial and ethnic differences in survival among Texas women with ovarian cancer: A population based study. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #143:S63, 2006.
69. Soliman PT, Tortolero-Luna G, Schmeler K, Milam M, Slomovitz B, Sun C, Brown J, Gershenson D, Lu K, Williams M, Betts P. Racial differences in survival among Texaswomen with endometrial cancer: A population-based study. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #182:S80, 2006.
70. Milam M, Celestino EJ, Slomovitz B, Schmeler K, Soliman PT, Broaddus R, Gershenson D, Wu W, Ellenson L, Lu K. Reduced progression of endometrial hyperplasis in PTEN heterozygote mice treated with the oral mTOR inhibitor RAD001. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting 17:59, 2006.
71. Milam MR, Ramirez P, Lu K, Bassett R Jr, Coleman R, Slomovitz B, Sood AK. Supracervical hysterectomy does not impact clinical outcome in patients with epithelial ovarian cancer: A case-control analysis. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #362:S155, 2006.
72. Moore RG, Brown Ak, Miller CM, Badgwell D, Lu Z, Verch T, Allard JW, Granai CO, Bast R, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer. Proceedings of the American Society of Clinical Oncologists 42nd Annual Meeting 24:5036, 2006.
73. Lu KH, Watts BG, Soliman PT, Boyd-Rogers SG, Daniels MS, Broaddus RR, Lynch PM, Peterson SK. A prospective pilot study of combined colon and endometrial cancer screening in women with HNPCC. Familial Cancer 4(Suppl 1):104-105, 2005.
74. PT Soliman, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Gershenson DM, Lu KH. Adiponectin as a marker for insulin resistance and endometrial cancer risk. Proceedings of the Society of Gynecologic Oncologists' 36th Annual Meeting:100 (#61), 2005.
75. Wu W, Soliman PT, Schmeler KM, Celestino J, Johnson CL, Walker CL, Lu KH. Association between loss of PTEN and cytoplasmic localization of p27 in endometrial cancer. Proceedings of AACR:#2866, 2005.
76. Slomovitz BM, Ramondetta LM, Crotzer D, Schmeler K, Broaddus RR, Sun CC, Gershenson DM, Burke TW, Lu KH. Clinical and pathologic review of clear cell carcinoma of the endometrium: A single institution study of 81 patients. Proceedings of the Society of Gynecologic Oncologists' 36th Annual Meeting:110 (#92), 2005.
77. Lu KH, Schorge JO, Rodabaugh KJ, Sun CC, Daniels MS, White KG, Soliman PT, Luthra R, Broaddus RR. Defining criteria for Lynch Syndrome/HNPCC in women under 50 with endometrial cancer: Final results of a prospective, multi-center study. Proceedings of the American Society of Clinical Oncology 41st Annual Meeting Vol. 23 (#9547), 2005.
78. Schmeler KM, Soliman PT, Sun CC, Oh JC, Slomovitz BM, Gershenson DM, Lu KH. Defining endometrial cancer risk factors for young, non-obese women. Proceedings of the Society of Gynecologic Oncologists’ 36th Annual Meeting:150 (#240), 2005.
79. Slomovitz BM, Coleman RL0, Soliman PT, Ramondetta LM, Wolf J, Sun CC, Gershenson DM, Burke TW, Lu KH. Is there a survival difference between clear cell and serous carcinoma of the endometrium? A stage and age-matched cohort study. Proceedings of the American Society of Clinical Oncology 41st Annual Meeting Vol. 23 (#5081), 2005.
80. Soliman PT, Schmeler KM, Broaddus RR, Slomovitz BM, Wu W, Gershenson DM, Lu KH. MTOR inhibition as a potential treatment for progesterone refractory endometrial nhyperplasia. Proceedings of the American Society of Clinical Oncology 41st Annual Meeting, Vol. 23 (#5080), 2005.
81. Broaddus RR, Green JS, Lynch HT, Chefn LM, Daniels MS, Conrad P, Munsell MF, White KG, Lutha R, Lu KH. Pathologic features of endometrial cancer associated with hereditary non-polyposis colorectal cancer. Familial Cancer 4(Suppl 1):76, 2005.
82. Slomovitz BM, Burke TW, Soliman PT, Ramondetta LM, Eifel PJ, Jhingran A, Wolf J, Sun CC, Gershenson DM, Lu KH. Patterns of recurrence of uterine papillary serous carcinoma. Proceedings of the Society of Gynecologic Oncologists' 36th Annual Meeting:108 (#83), 2005.
83. Lee CM, Slomovitz BM, Greer M, Sheena S, Gregurich MA, Burke T, Lu KH, Ramondetta LM. Practice patterns of SGO members for stage IIIA endometrial cancer. Proceedings of the Society of Gynecologic Oncologists' 36th Annual Meeting:132 (#173), 2005.
84. Schmeler KM, Soliman PT, Munsell MF, Daniels MS, White KG, Boyd-Rogers SG, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery for the reduction of gynecologic cancer risk in women with Lynch Syndrome/HNPCC. Proceedings of the American Society of Clinical Oncology 41st Annual Meeting Vol. 23 (#9531), 2005.
85. Soliman PT, Broaddus RR, Schmeler KM, Gonzalez D, Slomovitz BM, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: Do these women have HNPCC?. Familial Cancer 4(Suppl 1):128, 2005.
86. Lu KH, Schorge JO, Rodabaugh K, Daniels M, Tran N, Chung LH, Intengan M, Luthra R, Broaddus RR. A prospective, multi-center study to determine the prevalence of HNPCC-associated germline mutations in young women with endometrial cancer. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:406-407 (#29), 2004.
87. Slomovitz BM, Wu W, Soliman PT, Broaddus RR, Bodurka DC, Sun CC, Gershenson DM, Lu KH. Clinical and molecular characteristics of patients who develop breast cancer and uterine papillary serous carcinoma (UPSC). Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting, Vol. 92:423-424 (#67), 2004.
88. Soliman PT, Slomovitz BM, Sun CS, Gershenson DM, Lu KH. Endometrial cancer screening should be considered in women with colon cancer and one family member with HNPCC-related cancer. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:434 (#90), 2004.
89. Oh JC, Slomovitz BM, Soliman PT, Jhingran A, Lu KH. Endometrial cancer with ovarian involvement: does it matter if it is metastatic of dual primary?. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:437 (#97), 2004.
90. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen L, Allen B, Conrad P, Terdiman J, Burke TW, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecological malignancy as a "Sentinel Cancer" for women with HNPCC. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting, Vol. 92:421 (#61), 2004.
91. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Tarco E, Sun C, Wu W, Gershenson DM, Lu KH. Her-2/neu expression and amplification in uterine papillary serous carcinoma (UPSC). Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:435-436 (#93), 2004.
92. Ramondetta LM, Slomovitz BM, Caudell JJ, Lu KH, Broaddus RR, Gershenson DM, Deavers MT. Imatinib Mesylate (Gleevec)-targeted kinases are expressed in uterine sarcomas. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:481 (#196), 2004.
93. Oh JC, Wu W, Tortolero-Luna G, Broaddus RR, Gershenson DM, Burke TW, Lu KH. Increased plasma levels of IGF-2 and IGFBP-3 are associated with endometrial cancer risk. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:441-442 (#107), 2004.
94. Slomovitz BM, Wu W, Broaddus RR, Soliman PT, Celestino J, Thornton A, Wolf JK, Gershenson DM, Lu KH. Preclinical assessment of mTOR inhibition: A novel therapeutic target for the treatment of endometrial cancer. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:47-478 (#188), 2004.
95. Skates SJ, Horick NK, Finkelstein DM, Lu KH. Prospective multi-center high risk ovarian cancer screen trial: preliminary results from the first 2,000 women. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:411 (#39), 2004.
96. Chung LH, Broaddus RR, Vay A, Thornton A, Suh-Bergman B, Lu KH. PTEN expression increases in atypical endometrial hyperplasia successfully treated with progesterone. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting, Vol. 92:484-485 (#204), 2004.
97. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: A single institution review of 76 cases. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:482-483 (#199), 2004.
98. Slomovitz BM, Ramirez PT, Bodurka DC, Sun CC, Oh JC, Diaz P, Broaddus RR, Soliman PT, Gershensom DM, Lu KH. Tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vo. 92:404-405 (#24), 2004.
99. Lu K, Symecko H, Skates S, Finkelstein D. Cancer genetics network ovarian screening study: Physician practice patterns in screening women at high risk for ovarian cancer. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting, Vol. 22 (#1972), 2003.
100. Slomovitz B, Ramirez P, Bodurka D, Diaz P, Oh J, Burke T, Gershenson D, Lu K. Characteristics of endometrial carcinoma in patients with a history of breast cancer. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting Vol. 22 (#1867), 2003.
101. Slomovitz B, Oh J, Eifel P, Broaddus R, Silva E, Atkinson E, Burke T, Gershenson D, Lu K. Clinical and Pathologic Characteristics of Uterine Papillary Serous Carcinoma: Single Institution Review of 128 Cases. Gynecologic Oncology 88:p210 (#111), 2003.
102. Shvartsman H, Bodurka D, Sun C, Crispens M, Lu K, Silva E, Gershenson D. Comparative study of disease process and survival in patients with recurrent serous low malignant potential tumor of ovary versus low grade serous carcinoma. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting Vol. 22 (#1818), 2003.
103. Oh J, Slomovitz B, Broaddus R, Gershenson D, Burke T, Schmandt R, Lu K. Endometrial Cancer in Patients under 50: 161 Patients from a single institution. Gynecologic Oncology 88:218 (#129), 2003.
104. Lee C, Slomovitz B, Fletcher M, Hung M, Lu K, Sood A. Experimental/Molecular therapeutics 27: Target identification and Cell Cycle Mechanisms. Proceedings of the American Association for Cancer Research 94th Annual Meeting Vol. 44 (#2762), 2003.
105. Wang L, Liu J, Jain A, Luo R, Rosen D, Lu K, Yu Y, Bast R Jr. Expression of the tumor suppressor gene ARHI is maintained in well differentiated ovarian cancers and is associated with increased expression of p21WAF1/CIP1. Proceedings of the American Association for Cancer Research 94th Annual Meeting, Vol. 44 (#4941), 2003.
106. Slomovitz B, Celestino J, Chung L, Thornton A, Lu K. Frequent down-regulation of cdc25B and phosphorylated estrogen receptor alpha correlate with high-grade endometrial carcinomas. Proceedings of the American Association for Cancer Research 94th Annual Meeting Vol. 44 (#2301), 2003.
107. Marquez R, Baggerly K, Patterson A, Frumovitz M, Atkinson E, Liu J, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson D, Mills G, Bast R Jr, Lu K. Gene expression array analysis distinguishes different histotypes of epithelial ovarian cancer and suggests a distinct transcriptional program for mucinous cancers. Proceedings of the American Association for Cancer Research 94th Annual Meeting Vol. 44 (#2525), 2003.
108. Slomovitz B, Broaddus R, Thornton A, Oh J, Celestino J, Schmandt R, Burke T, Gershenson D, Lu K. Gleevec (Imatinib Mesylate) Targeted Kinases Are Activated in Most Endometrial Cancers. Gynecologic Oncology 88:207 (#106), 2003.
109. Slomovitz B, Lu K, Wu W, Oh J, Schmandt R, Celestino J, Thornton A, Gershenson D, Loose-Mitchell D, Broaddus R. IGF-1 receptor expression in endometrial carcinoma. Proceedings of the American Association for Cancer Research 94th Annual Meeting, Vol. 44 (#498), 2003.
110. Slomovitz B, Lu K, Wu W, Oh J, Schmandt R, Celestino J, Thornton A, Gershenson D, Loose-Mitchell D, Broaddus R. IGF-1 receptor expression in endometrial carcinoma. Proceedings of the American Association for Cancer Research 94th Annual Meeting 44:#498, 2003.
111. Chen Y, Saliba R, Rondon G, Giralt S, Lu K, Bodurka D, Gershenson D, Champlin R, Ueno N. Low prevalence of premature ovarian failure (POF) in women who received reduced-intensity conditioning (RIC) regimens for hematopoietic stem-cell transplanation (HST). Proceedings of the American Society of Clinical Oncology 39th Annual Meeting 22:#3350, 2003.
112. Skates S, Horick N, Finkelstein D, Lu K. Menopausal status and race affect normal CA125 cutpoints in high risk women: Initial results from the first 1249 subjects in a prospective multi-center ovarian cancer screening study in high risk women. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting, Vol. 22 (#382), 2003.
113. Lee C, Zia W, Deavers M, Slomovitz B, Thornton A, Hung M, Lu K. NF-KB is associated with a worse prognosis in high-grade serous ovarian carcinoma. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting, Vol. 22 (#1884), 2003.
114. Sun C, Bodurka D, Lu K, Efron B, Andersen R, Bevers T, Gershenson D, Bast R Jr. Perceptions of OVCA Risk and Screening: Differences between Women with a History of Breast Cancer (WHxBr) and Women with No History of Breast Cancer (WnoBr). Gynecologic Oncology 88:239 (#175), 2003.
115. Lu K, Patterson A, Atkinson E, Baggerly K, Marquez R, Liu J, Smith D, Hartman Ln, Fishman D, Berchuck A, Whitaker R, Gershenson D, Mills G, Bast R Jr. Selection of potential markers for epithelial ovarian cancer with gene expression array and recursive descent partition analysis. Proceedings of the American Association for Cancer Research 94th Annual Meeting Vol. 44 (#2520), 2003.
116. Liu J, Zhai J, Rosen D, Lu K, Broaddus R. The expression of mismatch repair gene hMLH6 is histotype specific. Modern Pathology 16:198A (#904), 2003.
117. Hartmann LC, Couch FJ, Kaufmann SH, Cliby WA, Iturria SJ, Kalli KR, Lu K, Bast B, Lillie J, Stec J, Shridhar V, Smith DI, Clark E. Chemoprediction in Ovarian Cancer-Genomic Approaches. Proceedings of the Society of Gynecologic Oncologist 33rd Annual Meeting:74 (#p 17), 2002.
118. Weigui W, Lu K, Liu J, Yung MS, Vincent M, Kudelka AP, Freedman R, Kavanagh J. Differential protein profile analysis of sera from normal donors and ovarian cancer patients by proteomics. Proceedings of the American Association for Cancer Research 93rd Annual Meeting, Vol. 43 (#189), 2002.
119. Malpica A, Deavers MT, Lu K, Liu J, Atkinson EN, Gershenson DM, Silva EG. Grading Ovarian Serous Carcinomas Using a Two-Tier System. Modern Pathology 15 (#849), 2002.
120. Vidal CI, Broaddus RR, Lu KH, Ellis LM, Arap W, Pasqualini R. Identification of molecular markers in ovarian cancer. Proceedings of the American Association for Cancer Research 93rd Annual Meeting, Vol. 43 (#3013), 2002.
121. Lee CM, Shvartsman H, Deavers MT, Xias W, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu K. Immunohistochemical analysis of b-catenin localization in low-grade and high grade serous ovarian carcinomas. Proceedings of the ASCO Volume 21:300 (#3018), 2002.
122. Oh J, Broaddus R, Totolero G, Gershenson DM, Burke TW, Schmandt R, Lu K. Insulin-like growth factors and endometrial cancer. Proceedings of the ASCO Vol 21:220a (#p 876), 2002.
123. Lu K, Kohlman W, Lynch P, Chen L, Allen B, Terdiman J, Lynch H, Tinley S et al. A consortium to study endometrial cancer in women with HNPCC. Proceedings of the 3rd Joint Meeting Leeds Castle Polyposis Group and International Collaborative Group Hereditary Non-Polyposis Colorectal Cancer:32, 2001.
124. Schmandt RE, Clifford SL, Lee J, Lillie J, Deavers M, Shaw P, Jung M, Levenback C, Bast R, Mills G, Gershenson DM, Lu KH. Differential expression of the secreted protease inhibitor, HE4, in epithelial ovarian cancer. Society of Gynecologic Oncologists 80:319, 2001.
125. Lu K, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen L, Allen B, Conrad P, Terdiman J, Burke T, Gershenson D, Lynch H, Lynch P, Broaddus R. Gynecological Malignancy as a "Sentinel Cancer" for Women with HNPCC. American Journal of Human Genetics 69:251, 2001.
126. Lu KH, Malpica AM, Bodurka-Bevers D, Shvartsman HS, Schmandt RE, Thornton A, Deavers MT, Silva EG, Gershenson DM. Immunohistochemical analysis of low grade serous ovarian carcinomas. Society of Gynecologic Oncologists 80:320, 2001.
127. Shvartsman HS, Lu KH, Clifford SL, Lee J, Lillie J, Deavers M, Jung M, Bast R, Mills G, Gershenson DM, Schmandt RE. Overexpression of NES-1 in epithelial ovarian cancer. Gynecol Oncol 80:319, 2001.
128. Gershenson DM, Tortolero-Luna GT, Deavers MT, Lu K, Wolf JK, Malpica A, Silva EG. Prognostic factors for relapse and survival in patients with stage II or III serous borderline ovarian tumors (BOT). Society of Gynecologic Oncology Abstract 76:240, 2000.
129. Bodurka-Bevers D, Lu K, Wolf JK, Bevers MW, Branham D, Silva EG, Gershenson DM. The clinical course of low-grade serous carcinomas of the ovary. Gynecol Oncol 76:254, 2000.
130. Lu KH, Garber J, Cramer D, Welch W, Berkowitz R, Muto M. Prophylactic oophorectomies in women at high risk for ovarian cancer. Proceedings of the Society of Gynecologic Oncologists Annual Meeting, 1999.
131. Lu KH, Cramer D, Muto M, Li E, Niloff J, Mok S. Frequency of BRCA1 mutations 185delAG and 5382insC and BRCA2 mutation 617delT in Ashkenazi Jewish women with epithelial ovarian cancer. Proceedings of the Society of Gynecologic Oncologists Annual Meeting 1998, 1998.
132. Lu KH, Bell D, Welch W, Berkowitz R, Mok S. Evidence for the multifocal origin of serous borderline ovarian tumors. Proceedings of the American Association for Cancer Research Annual Meeting, 1997.
133. Laufer MR, Townsend NL, Parsons KE, Brody KA, Lu KH, Diller LR, Emans SJ, Guinan EC. The use of leuprolide acetate for the induction of amenorrhea in women undergoing bone marrow transplantation (BMT): A pilot study. Proceedings of the American Society of Clinical Oncology Annual Meeting, 1995.

Book Chapters

1. Burke T, Jhingran A, Lu K, Broaddus R. Endometrial Cancer. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Chapter 11. Ed(s) MA Rodriguez, RS Walters, TW Burke. Springer: New York, 109-118, 2013.
2. Lu KH, Berchuck A, Kauff ND. Hereditary Gynecologic Cancers. In: Principles and Practice of Gynecologic Oncology. Chapter 3, 6th. Ed(s) RR Barakat, A Berchuck, M Markman, ME Randall. Lippincott Williams & Wilkins: Maryland, 60-71, 2013.
3. Lu KH, Klopp AH, Soliman PT. Increased Adiposity and Endometrial Cancer Risk. In: Adipose Tissue and Cancer. Ed(s) MG Kolonin. Springer: New York, NY, 53-70, 2013. ISBN: 978-1-4614-7659-7.
4. Iglesias DA, Huang M, Soliman PT, Djordjevic, Lu KH. Endometrial Hyperplasia and Cancer. In: Gynecologic Oncology Clinical Practice & Surgical Atlas. Chapter 6. Ed(s) BY Karlan, RE Bristow, AJ Li. McGraw Hill: China, 105-138, 2012. ISBN: 978-0-07-174926-8.
5. Soliman PT and Lu KH. Neoplastic Diseases of the Uterus. In: Comprehensive Gynecology, 6th. Ed(s) Gretchen M. Lentz, MD, Roger A. Lobo, MD, David M. Gershenson, MD, Vern L. Katz, MD. Elsevier Mosby: Philadelphia, PA, 713-730, 2012.
6. Mok SC, Wong KK, Lu K, Munger K, Nagymanyoki Z. Molecular Basis of Gynecologic Diseases. In: Essential Concepts in Molecular Pathology. Chapter 23. Ed(s) WR Coleman and GJ Tsongalis. Academic Press: Burlington, MA, 309-322, 2010.
7. Lu KH. Clinical Relevance of Hereditary Endometrial Cancer. In: Hereditary Gynecologic Cancer: Risk, Prevention, and Management. Informa Healthcare: New York City, NY, 2008.
8. Lu KH. Karen H. Lu, MD. In: Legends and Legacies: Personal Journeys of Women Physicians and Scientists at M.D. Anderson Cancer Center. Ed(s) EL Travis, PhD. The U T M.D. Anderson Cancer Center: Houston, TX, 107-115, 2008.
9. Lu KH, Keeler ER. Ovarian Cancer Screening. In: Early Diagnosis of Ovarian Cancer. Elsevier: Philadelphia, Pennsylvania, 2008.
10. Lu KH, Broaddus R. Endometrial Cancer Associated with Defective DNA Mismatch Repair. In: Prognostic and Predictive Factors in Gynecologic Cancers. Ed(s) C Levenback, R Coleman, K Lu, A Sood. Informa UK, Ltd: London, England, 185-196, 2007.
11. Lu KH, Skates S. Hereditary Breast Cancer. In: Prognostic and Predictive Factors in Gynecologic Cancers. Ed(s) T Rebbick, C Isaccs. Informa UK Ltd: London, England, 2007.
12. Lu KH, Slomovitz B. Neoplastic Diseases of the Uterus. In: Comprehensive Gynecology. Chapter 32, 5th. Ed(s) VL Katz, G Lentz, R Lobo, D Gershenson. Informa UK Ltd: Longdon, England, 818-838, 2007.
13. Lu KH. Organ Specific Cancer Control. In: Gynecologic Cancers, ASCOs Cancer Prevention Curriculum, 2007.
14. Lu KH. Prevention and Early Detection of Endometrial and Ovarian Cancers. In: Gynecologic Cancer. Chapter 2. Ed(s) PJ Eifel, DM Gershenson, JJ Kavanagh, EG Silva. Spring Scient and Business Media Inc, 12-19, 2006.
15. Lu KH, Bell D. Borderline Ovarian Tumors. In: Gynecologic Cancer: Controversies in Management,. Elsevier Ltd,, Pg 519-526, Chapter 40, 2004.
16. Ramondetta, LM, Lu KH. Controversies in endometrial cancer screening and diagnosis. . In: Gynecologic Cancer: Controversies in Management. Pg 241-247. Elsevier Ltd, Chapter 17, 2004.
17. Lu KH, Gershenson DM, Poynor EA, Sabbatini PJ. Germ-cell and ovarian sex cord-stromal tumors. In: MSKCC-MDACC Handbook of Gynecologic Oncology. Martin Dunitz Publishers, Ltd., Pg 271-82, Chapter 15, 2002.
18. Burke TW, Lu KH. Surgical Treatment of Invasive Cervical Cancer. In: ACS Atlas of Clinical Oncology: Cancer of the Female Lower Genital Tract. B.C. Decker Inc., 133-145, 2001.

Books (edited and written)

1. Lu KH. Ed(s) KH Lu. Hereditary Gynecologic Cancer: Risk, Prevention and Management. Informa NYC: New York, NY, 2008.
2. C Levenback, R Coleman, K Lu, A Sood. Prognostic and Predictive Factors in Gynecologic Cancers. Informa UK Ltd: London, England, 2007.

Letters to the Editor

1. Slomovitz BM, Lu KH. LTE - Commenting on "HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?". Gynecol Onc 88:263-5, 2003.

Manuals, Teaching Aids, Other Teaching Publications

1. Lu KH, Mutch DG. Clinical Implications of Genetic Testing for Cancer Susceptilibility. 35. Ed(s) Sokol RJ, Stone ML. The American College of Obstetricians and Gynecologists: Port Washington, NY, 1-9, 2/2010.
2. Lu K. Understanding endometrial cancer: A woman's guide. Gynecologic Cancer Foundation, 2006.
3. Lu K. Ovarian Cancer Educational CD-ROM Series. TLM Japan, 2005.
4. Lu K, Smith JA. Chemotherapy Regimens for Gynecologic Malignancies, 2004.
5. Lu K, Smith JA. Chemotherapy Regimens for Gynecologic Malignancies, 2003.

Grant & Contract Support

Title: M. D. Anderson Cancer Center Gynecologic Cancer SPORE for Uterine Cancers
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2010 - 8/31/2015
 
Title: Lipotoxicity and Obesity Related Risk of Endometrial Carcinoma
Funding Source: UTHSC-Houston
Role: Co-Principal Investigator
Principal Investigator: Perry Bickel, MD
Duration: 9/1/2008 - present
 
Title: Predictors of Survival: Chemotherapy in Ovarian Cancer
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator-MDACC
Principal Investigator: Dong Liang, PhD
Duration: 7/1/2007 - 6/30/2012
 
Title: M. D. Anderson Cancer Center-Ciphergen Collaboration in the Field of Gynecologic Disease
Funding Source: Ciphergen Biosystems, Inc.
Role: Principal Investigator
Duration: 10/1/2006 - 11/30/2007
 
Title: UPRCC/NDACC: Partnership for Excellence in Cancer Research
Funding Source: NIH/NCI
Role: Principal Investigator-Pilot Project C
Principal Investigator: Gabriel Lopez-Berestein, MD
Duration: 9/22/2006 - 8/31/2012
 
Title: Ovarian Cancer Proteomics Collaborative Trial
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 9/1/2005 - 8/31/2008
 
Title: The Lynne Cohen High Risk Screening & Prevention Project for Ovarian and Breast Cancer
Funding Source: The Lynne Cohen Foundation for Ovarian Cancer Research
Role: Principal Investigator
Duration: 4/1/2005 - 8/31/2012
 
Title: Annual Uterine Cancer Symposium
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2004 - 8/31/2011
 
Title: Ovarian Cancer Screening Trial in High Risk Women (Cancer Genetics Network/CGN)
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Steven Skates, MD
Duration: 7/1/2004 - 6/30/2008
 
Title: Endometrial Cancer Translational Research Program
Funding Source: UT M. D. Anderson Cancer Center Multidisciplinary Research Program (MRP)
Role: Principal Investigator
Duration: 5/1/2002 - present
 
Title: Modulation of putative surrogate endpoint biomarkers in endometrial biopsies from women with HNPCC
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/30/2000 - 9/30/2009
 
Title: Specialized Program of Research Excellence in Ovarian Cancer
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Robert C. Bast, M.D.
Duration: 9/30/1999 - 8/31/2016

Last updated: 4/27/2016